Hybrid & Bioconjugate Peptides

Integrated peptide conjugation strategies

Glycopeptides, lipopeptides, peptide–oligonucleotide conjugates, and peptide–small molecule hybrids engineered for function, targeting, and delivery.

Glycopeptides
Lipopeptides
Peptide–Oligo Conjugates
Peptide–Small Molecule Hybrids

Overview

Bio-Synthesis provides hybrid and bioconjugate peptide synthesis services that integrate peptides with carbohydrates, lipids, oligonucleotides, and small molecules. These conjugates enable targeted delivery, multivalent recognition, assay development, and functional studies across immunology, diagnostics, and drug discovery.

Why build peptide conjugates?
  • Function: combine peptide specificity with glycan, lipid, oligo, or drug functionality.
  • Targeting: improve localization or uptake via defined handles and linkers.
  • Control: reproducible attachment sites for consistent performance.
Typical applications
  • Glyco-epitope presentation and receptor recognition studies
  • Membrane targeting and lipopeptide adjuvants
  • Peptide–oligo delivery and diagnostics
  • Peptide–drug conjugates and imaging probes

Best-fit when you need

Defined attachment site

Control conjugation position to protect the binding face.

Linker strategy

Tune length, flexibility, and optional cleavability.

Extra QC confidence

Confirm composition and architecture for reproducibility.

Looking for a hub? Return to Advanced Peptide Synthesis.

Quick Specification Table (Services at a Glance)

Use this table to map your project to the right hybrid format. For detailed options, see the service sections below.

Service What it is Key design inputs Common use cases
Glycopeptide Synthesis Peptides conjugated with defined carbohydrate moieties. Glycan identity, attachment site, linker chemistry, glycoform control needs. Immunology, receptor recognition, vaccine research.
Lipopeptide Synthesis Peptides modified with lipid chains or lipidated scaffolds. Lipid type/length, attachment site, solubility strategy. Membrane targeting, adjuvants, delivery systems.
Peptide–Oligonucleotide Conjugates Peptides covalently linked to DNA/RNA/modified oligos. Oligo chemistry/length, peptide handle, linker/cleavage design. Targeted delivery, diagnostics, gene modulation tools.
Peptide–Small Molecule Hybrids Peptides conjugated to drugs, dyes, probes, or small molecules. Small molecule structure, attachment point, linker choice (cleavable vs stable). Peptide–drug conjugates, imaging, assay development.

Related service pages (internal links)

For full options, pricing drivers, and examples, visit the dedicated pages:

Technical Notes — Information that speeds quoting
Project inputs
  • Peptide sequence(s) and desired conjugate type (glyco / lipo / oligo / small molecule).
  • Attachment site and preferred handle (Cys, azide/alkyne, amine, etc.).
  • Target purity/scale and any formulation constraints.
Success criteria
  • Define your readout (binding, uptake, activity, imaging, stability).
  • Specify linker needs (length, flexibility, cleavable vs stable).
  • Tell us if you need extra QC (mapping, state verification, documentation).

Glycopeptide Synthesis Services

Glycopeptide synthesis attaches defined carbohydrate moieties to peptides to study glyco-epitopes, receptor recognition, and immune interactions. We can support site-specific glycosylation and linker strategies aligned to your assay or application.

Design option Typical choices
Glycan identity Defined glycan structures (project-dependent); specify desired glycoform(s).
Attachment site N-terminus, C-terminus, or internal site (selected to preserve activity).
Linker strategy Direct vs spacer/linker for accessibility; optional cleavability.
Additional handles Optional labels or orthogonal handles for downstream conjugation.
Technical Notes — Glycopeptide design
Design guidance
  • Provide the desired glycan structure(s) and any required isomers.
  • Choose an attachment site that does not block the binding face.
  • Consider a spacer if the glycan must be more exposed for recognition.
Deliverables
  • Purified glycopeptide + CoA (typical).
  • LC–MS confirmation; mapping options upon request.
  • Documentation aligned to project needs.

Related: Glycopeptide synthesis service page.

Lipopeptide Synthesis Services

Lipopeptide synthesis adds lipid moieties that can enhance membrane association, improve uptake, or provide adjuvant-like behavior. Lipid selection and placement strongly influence solubility and performance.

Design option Typical choices
Lipid type/length Project-dependent; define chain length and saturation where relevant.
Attachment site N-terminus, lysine side chain, or defined internal handle.
Solubility strategy Spacer/linker choices; balancing residues if required.
Additional modifications Labels, biotin, click handles, or cleavable linkers as needed.
Technical Notes — Lipidation & handling
Common pitfalls
  • Lipidation can increase hydrophobicity; plan solubility early.
  • Attachment site can affect activity; preserve the binding face.
  • Define formulation constraints for delivery or assays.
Deliverables
  • Purified lipopeptide + CoA (typical).
  • LC–MS confirmation; additional analytics upon request.
  • Handling notes for solubilization and storage.

Related: Lipopeptide synthesis service page.

Peptide–Oligonucleotide Conjugates Services

Peptide–oligonucleotide conjugates combine peptide targeting or cell-penetrating elements with DNA/RNA cargo. Linker chemistry and handle placement are critical for conjugation efficiency and biological performance.

Design option Typical choices
Oligo chemistry DNA/RNA/modified oligos; define length and any modifications.
Conjugation handle Thiol, amine, azide/alkyne, or other orthogonal handle (project-dependent).
Linker strategy Stable vs cleavable; tune length for accessibility.
Orientation Peptide-to-5′ or 3′ attachment; define if orientation matters.
Technical Notes — Conjugation strategy
Design guidance
  • Specify oligo sequence/length and any base/sugar modifications.
  • Tell us if you need a cleavable linker (endosomal release, etc.).
  • Define which end (5′/3′) should carry the peptide.
QC options
  • Confirm mass and purity for the conjugate.
  • Optional additional documentation for regulated workflows.
  • Batch reproducibility support for screening programs.

Related: Peptide–oligonucleotide conjugates service page.

Peptide–Small Molecule Hybrids Services

Peptide–small molecule hybrids link peptides to drugs, dyes, or probes to create targeted conjugates and functional tools. Linker design and attachment site selection are key to preserving activity.

Design option Typical choices
Small molecule type Drug, dye, imaging probe, affinity tag, or other payload.
Attachment point Defined site on peptide (N/C terminus or side chain) and on payload.
Linker choice Stable vs cleavable; tune length and polarity.
Functional handle Optional orthogonal chemistry (click/thiol) for modular assembly.
Technical Notes — Preserve activity
Design guidance
  • Choose an attachment site away from key binding residues.
  • Use linkers to reduce steric effects from bulky payloads.
  • Specify whether payload release (cleavable linkers) is required.
Deliverables
  • Purified hybrid conjugate + CoA (typical).
  • LC–MS confirmation; optional additional analytics.
  • Documentation aligned to your program needs.

Related: Peptide–small molecule hybrids service page.

FAQ

What information do you need to quote glycopeptide synthesis?

Provide the peptide sequence, the desired glycan structure(s), the attachment site, any linker preference, and your target purity/scale. If you have assay constraints, include them so we can recommend accessibility and spacer options.

Do lipopeptides require special handling?

Often yes. Lipidation can increase hydrophobicity. Tell us your formulation constraints and we can recommend linker/sequence strategies and provide handling guidance for solubilization and storage.

Can you make peptide–oligonucleotide conjugates with specific 5′/3′ orientation?

Yes. Specify whether the peptide should attach to the 5′ or 3′ end (or internally), along with the oligo chemistry and any required modifications.

Should I choose a cleavable linker for peptide–drug conjugates?

Choose cleavable linkers when payload release is part of the mechanism (e.g., intracellular release). Choose stable linkers when you need the conjugate to remain intact during binding or imaging.

Can you include click chemistry or cysteine handles in hybrid conjugates?

Yes. We can incorporate orthogonal handles (azide/alkyne, cysteine, amines) to support modular assembly and site-specific conjugation—planned into the design.

What QC do you provide for peptide conjugates?

Typical deliverables include purity reporting and LC–MS confirmation. For complex architectures, additional characterization (e.g., mapping or state verification) can be added to support reproducibility and downstream workflows.

CONTACT US

Speak to a Bioconjugation Peptide Scientist

Share your peptide sequence(s), conjugate type (glyco, lipo, oligo, small molecule), linker/handle requirements, and intended application. We’ll recommend practical specifications and a synthesis/QC plan aligned to your goals.

Tip: If the peptide is hydrophobic/long/cysteine-rich, include that context so we can route the request to the right synthesis strategy.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.